Document is current

Article History

Received: 7 June 2024

Accepted: 24 September 2024

First Online: 8 October 2024

Declarations

:

: The protocol was approved by the Vall d’Hebron University Hospital Ethical Research Committee PR(AG)463/2022 and Hospital Clinic Ethical Committee HCB/2022/0279. All methods were carried out in accordance with applicable guidelines and regulations.The study protocol is also registered in the Clinical Trials Registry (Trial Registration) at ClinicalTrials.gov with the identifier ID: NCT06238414. Date of registration: 1st February 2024, final update is protocol version 3.0, 19th March 2024.Any protocol amendment that implies a protocol modification will be communicated to the investigators, institutes of research involved (VHIR and IDIBAPS), ethics committees, and the sponsor (La Marató de TV3 Foundation).

: Not applicable.

: We are currently recruiting participants for the trial.

: The results will be written up in manuscripts. Additionally, the findings will be presented in platforms for discussion such as national and international conferences or seminars.

: J.A.R.Q was on the speakers’ bureau and/or has acted as a consultant for Biogen, Idorsia, Janssen-Cilag, Novartis, Takeda, Bial, Sincrolab, Neuraxpharm, Novartis, BMS, Medice, Rubió, Uriach, Technofarma and Raffo in the last 3 years. He also received travel grants (air tickets + hotel) to attend psychiatric meetings held by Idorsia, Janssen-Cilag, Rubió, Takeda, Bial and Medice. The Department of Psychiatry that he chairs has received unrestricted educational and research support from the following companies in the last 3 years: Exeltis, Idorsia, Janssen- Cilag, Neuraxpharm, Oryzon, Roche, Probitas, Psious, and Rubió.